Celyad Oncology H1 FY26 net loss narrows to €1.2 million; operating loss narrows to €1.2 million

By Public Technologies
  • Celyad Oncology posted a net loss of €1.2 million for the first half, narrowing from €3.7 million a year earlier.
  • Operating loss narrowed to €1.2 million from €3.7 million, while employee benefit expense fell 71.43% to €0.4 million.
  • Other operating expenses dropped 64% to €1 million, and net cash used in operations decreased 54.55% to €1.5 million.
  • Cash and cash equivalents stood at €0.1 million at June 30, and a €0.5 million capital increase on July 16 strengthened liquidity.
  • The group expects existing cash and cash equivalents to fund operating and capital expenditures into 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celyad Oncology SA published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.